Newbury Pharmaceuticals AB (publ) (STO:NEWBRY)
Sweden · Delayed Price · Currency is SEK 2.600
-0.020 (-0.76%)
Jul 25, 2025, 5:29 PM CET
STO:NEWBRY Revenue
Newbury Pharmaceuticals AB had revenue of 6.69M SEK in the quarter ending May 31, 2025, with 382.40% growth. This brings the company's revenue in the last twelve months to 46.78M, up 152.42% year-over-year. In the fiscal year ending August 31, 2024, Newbury Pharmaceuticals AB had annual revenue of 36.83M with 258.75% growth.
Revenue (ttm)
46.78M
Revenue Growth
+152.42%
P/S Ratio
1.69
Revenue / Employee
6.68M
Employees
5
Market Cap
79.03M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2024 | 36.83M | 26.56M | 258.75% |
| Aug 31, 2023 | 10.27M | 4.75M | 86.11% |
| Aug 31, 2022 | 5.52M | 2.43M | 78.73% |
| Aug 31, 2021 | 3.09M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full Definition